贝伐珠单抗联合索拉非尼治疗复发卵巢癌(含或不含既往贝伐珠单抗治疗)的II期试验
该II期试验在54例复发卵巢癌患者中评估贝伐珠单抗联合索拉非尼,分贝伐珠单抗初治组(41例)和经治组(13例)。初治组35例可评估者中9例(26%)达部分缓解,经治组无缓解。联合方案未达到预设主要终点,但初治组可见临床活性,需密切监测毒性并调整剂量。
要点
- 贝伐珠单抗初治组35例可评估者中9例(26%)达部分缓解,18例稳定≥4个月。
- 贝伐珠单抗经治组无缓解,7例(54%)稳定≥4个月。
- 治疗相关3/4级不良事件≥5%包括高血压(17/54,31%)和静脉血栓或肺栓塞(5/54,9%)。
核心结论
- 贝伐珠单抗联合索拉非尼未达到预设主要终点,但在既往重度治疗、铂耐药且贝伐珠单抗初治的卵巢癌患者中可见一定临床活性。
- 预期的类别毒性需密切监测并调整剂量。
研究设计与样本
- II期试验,采用Simon两阶段最优设计,主要终点为缓解率,次要终点为无进展生存期(PFS)和毒性。
- 2007年3月至2012年8月共入组54例女性,贝伐珠单抗初治组41例,贝伐珠单抗经治组13例;既往系统治疗中位数分别为5(2-9)和6(5-9)线。
- 给药方案:贝伐珠单抗5 mg/kg静脉每2周一次,联合索拉非尼200 mg每日两次,用药5天停2天。
- 探索性相关研究包括血浆细胞因子浓度、组织蛋白质组学和动态对比增强磁共振成像(DCE-MRI)。
主要发现
- 贝伐珠单抗初治组35例可评估者中9例(26%)达部分缓解,18例稳定≥4个月。
- 贝伐珠单抗经治组无缓解,7例(54%)稳定≥4个月,其中1例稳定达27个月。
- 总体中位PFS为5.5个月(95%CI:4.0-6.8个月)。
- 治疗相关3/4级不良事件(≥5%)包括高血压17/54(31%;3级16例,4级1例)和静脉血栓或肺栓塞5/54(9%;3级4例,4级1例)。
- 治疗前低IL8浓度与PFS≥4个月相关(p = .031)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether blocking multiple points of the angiogenesis pathway by addition of sorafenib, a multi-kinase inhibitor against VEGFR2/3, Raf, c-Kit, and PDGFR, to bevacizumab would yield clinical activity in ovarian cancer (OvCa). METHODS: This phase II study tested bevacizumab plus sorafenib in two cohorts; bevacizumab-naïve and bevacizumab-exposed patients. Bevacizumab (5 mg/kg IV every 2 weeks) was given with sorafenib 200 mg bid 5 days-on/2 days-off. The primary objective was response rate using a Simon two-stage optimal design. Progression-free survival (PFS) and toxicity were the secondary endpoints. Exploratory correlative studies included plasma cytokine concentrations, tissue proteomics and dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI). RESULTS: Between March 2007 and August 2012, 54 women were enrolled, 41 bevacizumab-naive and 13 bevacizumab-prior, with median 5 (2-9) and 6 (5-9) prior systemic therapies, respectively. Nine of 35 (26%) evaluable bevacizumab-naive patients attained partial responses (PR), and 18 had stable disease (SD) ≥ 4 months. No responses were seen in the bevacizumab-prior group and 7 (54%) patients had SD ≥ 4 months, including one exceptional responder with SD of 27 months. The overall median PFS was 5.5 months (95%CI: 4.0-6.8 months). Treatment-related grade 3/4 adverse events (≥5%) included hypertension (17/54 [31%]; grade 3 in 16 patients and grade 4 in one patient) and venous thrombosis or pulmonary embolism (5/54 [9%]; grade 3 in 4 patients and grade 4 in one patient). Pretreatment low IL8 concentration was associated with PFS ≥ 4 months (p = .031). CONCLUSIONS: The bevacizumab and sorafenib combination did not meet the pre-specified primary endpoint although some clinical activity was seen in heavily-pretreated bevacizumab-naive OvCa patients with platinum-resistant disease. Anticipated class toxicities required close monitoring and dose modifications.
引用
- Lee JM, Annunziata CM, Hays JL, et al. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. Gynecol Oncol. 2020. PMID: 32747013. doi:10.1016/j.ygyno.2020.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。